First Gene Therapy Approval on the Horizon: The Impact on Ophthalmology
July 23, 2012
As Andrew Pollack writes in today’s NYTimes, “After more than two decades of dashed expectations, the field of gene therapy appears close to reaching a milestone: a regulatory approval. The European Medicines Agency has recommended approval of a gene therapy to treat a rare genetic disease.”
The therapy recommended for approval in Europe, called Glybera, was developed by uniQure, a Dutch company. It treats lipoprotein lipase deficiency, a disease that affects only several hundred people in the European Union and a similar number in North America.
People with the disease have a genetic mutation that prevents them from producing an enzyme needed to break down certain fat-carrying particles that circulate in the bloodstream after meals. Without the enzyme, so much fat can accumulate that the blood looks white rather than red.
The reason I believe that this is important is because it brings “legitimacy” to the whole field of regenerative medicine. As readers of this online Journal are aware, my interest is in the field of ophthalmology. As you may be further aware, I am currently tracking sixteen clinical trials using gene therapy to treat eye diseases. Several of these are showing promising results and the above approval, when it comes, will bring increased attention to the whole of this field, including the ophthalmic trials.
To read more, please follow this link.
You might also enjoy...
- Will 2012 be the Year for Gene Therapy in Ophthalmology?
- Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells
- Current Status of Stem Cells and Gene Therapy in Ophthalmology
- Vision Improvement 1 Year after Gene Therapy in Leber’s Amaurosis
- Researchers Use Non-Viral Gene Therapy to Prevent Retinal Degeneration
Jump down to form below to submit your own comments